D
Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
D
Sell
2/11/2025Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D from D+ on 2/11/2025 due to a significant decline in the valuation index, efficiency index and solvency index.
Roivant Sciences Ltd. (ROIV) was downgraded to D from D+ on 2/11/2025 due to a significant decline in the valuation index, efficiency index and solvency index.
D
Sell
1/10/2025Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D+ from C- on 1/10/2025 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from $0.121 to -$0.313, the quick ratio declined from 27.41 to 9.72, and total revenue declined 43.99% from $7.99M to $4.48M.
Roivant Sciences Ltd. (ROIV) was downgraded to D+ from C- on 1/10/2025 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from $0.121 to -$0.313, the quick ratio declined from 27.41 to 9.72, and total revenue declined 43.99% from $7.99M to $4.48M.
C
Hold
2/13/2024Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to C- from D- on 2/13/2024 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 1,774.58% from -$304.33M to $5.1B, the quick ratio increased from 5.51 to 27.5, and total capital increased 288.85% from $1.82B to $7.09B.
Roivant Sciences Ltd. (ROIV) was upgraded to C- from D- on 2/13/2024 due to a significant increase in the valuation index, efficiency index and solvency index. Net income increased 1,774.58% from -$304.33M to $5.1B, the quick ratio increased from 5.51 to 27.5, and total capital increased 288.85% from $1.82B to $7.09B.
D
Sell
3/14/2023Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 03/14/2023.
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 03/14/2023.
D
Sell
2/14/2023Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 02/14/2023.
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 02/14/2023.
D
Sell
2/8/2023Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/18/2022Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 11/18/2022 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 190.18% from $4.32M to $12.53M, operating cash flow increased 24.77% from -$252.08M to -$189.63M, and earnings per share increased from -$0.4768 to -$0.42.
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 11/18/2022 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 190.18% from $4.32M to $12.53M, operating cash flow increased 24.77% from -$252.08M to -$189.63M, and earnings per share increased from -$0.4768 to -$0.42.
D
Sell
8/17/2022Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 8/17/2022 due to a large decline in the solvency index, growth index and volatility index. EBIT declined 171.43% from -$104.01M to -$282.31M, debt to equity increased from 0.13 to 0.31, and operating cash flow declined 70.94% from -$147.47M to -$252.08M.
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 8/17/2022 due to a large decline in the solvency index, growth index and volatility index. EBIT declined 171.43% from -$104.01M to -$282.31M, debt to equity increased from 0.13 to 0.31, and operating cash flow declined 70.94% from -$147.47M to -$252.08M.
D
Sell
8/4/2022Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index, total return index and valuation index.
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
7/19/2022Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 7/19/2022 due to a decline in the volatility index.
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 7/19/2022 due to a decline in the volatility index.
D
Sell
6/29/2022Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 6/29/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 57.72% from -$246.02M to -$104.01M, operating cash flow increased 45.08% from -$268.49M to -$147.47M, and earnings per share increased from -$0.4144 to -$0.3899.
Roivant Sciences Ltd. (ROIV) was upgraded to D from D- on 6/29/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 57.72% from -$246.02M to -$104.01M, operating cash flow increased 45.08% from -$268.49M to -$147.47M, and earnings per share increased from -$0.4144 to -$0.3899.
D
Sell
6/21/2022Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D- from E+ on 6/21/2022 due to an increase in the volatility index.
Roivant Sciences Ltd. (ROIV) was upgraded to D- from E+ on 6/21/2022 due to an increase in the volatility index.
E
Sell
6/6/2022Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to E+ from D- on 6/6/2022 due to a decline in the volatility index and total return index.
Roivant Sciences Ltd. (ROIV) was downgraded to E+ from D- on 6/6/2022 due to a decline in the volatility index and total return index.
D
Sell
5/16/2022Upgraded
Roivant Sciences Ltd. (ROIV) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
Roivant Sciences Ltd. (ROIV) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index and volatility index.
Roivant Sciences Ltd. (ROIV) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
2/16/2022Downgrade
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 2/16/2022 due to a major decline in the efficiency index, growth index and total return index. Operating cash flow declined 122.64% from -$120.6M to -$268.49M, net income declined 36.48% from -$208.48M to -$284.54M, and earnings per share declined from -$0.3206 to -$0.4144.
Roivant Sciences Ltd. (ROIV) was downgraded to D- from D on 2/16/2022 due to a major decline in the efficiency index, growth index and total return index. Operating cash flow declined 122.64% from -$120.6M to -$268.49M, net income declined 36.48% from -$208.48M to -$284.54M, and earnings per share declined from -$0.3206 to -$0.4144.
D
Sell
11/3/2021None
Roivant Sciences Ltd. (ROIV) was downgraded to D from U on 11/03/2021.
Roivant Sciences Ltd. (ROIV) was downgraded to D from U on 11/03/2021.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
